Key result
Valsartan matches ACE inhibitors for preventing post-AMI LV dysfunction with ~73% fewer adverse reactions.
Why the study?
Does valsartan prevent left ventricular dysfunction and remodeling as effectively as ACE inhibitors in Japanese patients with acute myocardial infarction?
RCT (n=241)
Randomly allocated
Yes
Does valsartan prevent left ventricular dysfunction and remodeling as effectively as ACE inhibitors in Japanese patients with acute myocardial infarction?
Valsartan is as effective as ACE inhibitors in preventing left ventricular remodeling after acute myocardial infarction in Japanese patients, while offering a significantly better tolerability profile.
Answers are grounded in this paper and cite their sources.
Supports valsartan preference over ACE inhibitors post-MI for equivalent efficacy and better tolerability; confirms RCT findings in Japanese patients.
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEI) reduce the mortality in the chronic phase of myocardial infarction (MI), and similar effects of angiotensin receptor blockers (ARB) have been reported. However, these effects of ARB have not yet been established in Japanese patients. A multicenter randomized study was designed for the present study to examine the effect of valsartan as compared to that of ACEI against left ventricular dysfunction after MI. METHODS AND RESULTS: Patients with acute MI were randomly allocated to either the valsartan group (n=120; mean age 63 +/-1.0) or the ACEI group (n=121; mean age 62.9 +/-1.0) and followed up until 6 months. Left ventriculography was performed during hospital admission and at 6 months. The blood pressure was similar in the 2 groups throughout the study. The incidences of cardiovascular events and target vessel revascularization were similar, although that of adverse events was significantly higher in the ACEI (12.4%) than in the valsartan group (3.3%; P<0.05). There were no differences in left ventricular ejection fraction and left ventricular end-diastolic volume index between the groups. CONCLUSIONS: Valsartan exhibits similar efficacy effective to that of ACEI in preventing left ventricular dysfunction in Japanese patients with acute MI, and is, in addition, better tolerated than ACEI.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2009) conducted an RCT in Acute myocardial infarction (n=241). Valsartan vs. Angiotensin-converting enzyme inhibitors (ACEI) was evaluated on Left ventricular ejection fraction at 6 months (%) (p=NS). Valsartan exhibited similar efficacy to ACE inhibitors in preventing left ventricular dysfunction after acute myocardial infarction, but had a lower incidence of adverse drug reactions.
Synapse has enriched 10 related papers. Consider them for comparative context: